JP2022518232A5 - - Google Patents
Info
- Publication number
- JP2022518232A5 JP2022518232A5 JP2021541578A JP2021541578A JP2022518232A5 JP 2022518232 A5 JP2022518232 A5 JP 2022518232A5 JP 2021541578 A JP2021541578 A JP 2021541578A JP 2021541578 A JP2021541578 A JP 2021541578A JP 2022518232 A5 JP2022518232 A5 JP 2022518232A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- cancer
- composition according
- diazo
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962794231P | 2019-01-18 | 2019-01-18 | |
| US62/794,231 | 2019-01-18 | ||
| PCT/US2020/014149 WO2020150639A1 (en) | 2019-01-18 | 2020-01-17 | Combinaton therapy with a don prodrug and an immune checkpoint inhibitor |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022518232A JP2022518232A (ja) | 2022-03-14 |
| JP2022518232A5 true JP2022518232A5 (enExample) | 2023-01-27 |
| JP7574198B2 JP7574198B2 (ja) | 2024-10-28 |
Family
ID=71614516
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021541578A Active JP7574198B2 (ja) | 2019-01-18 | 2020-01-17 | Ｄｏｎプロドラッグおよび免疫チェックポイント阻害剤による組み合わせ治療法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20220117938A1 (enExample) |
| EP (1) | EP3911310A4 (enExample) |
| JP (1) | JP7574198B2 (enExample) |
| KR (1) | KR20210117303A (enExample) |
| CN (1) | CN113438947A (enExample) |
| AU (1) | AU2020208637A1 (enExample) |
| BR (1) | BR112021014112A2 (enExample) |
| CA (1) | CA3126822A1 (enExample) |
| EA (1) | EA202191992A1 (enExample) |
| IL (1) | IL284907A (enExample) |
| MX (1) | MX2021008546A (enExample) |
| SG (1) | SG11202107317WA (enExample) |
| WO (1) | WO2020150639A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220332676A1 (en) * | 2019-10-03 | 2022-10-20 | Dracen Pharmaceuticals, Inc. | Lyophilized composition comprising (s)-isopropyl 2-((s)-2-acetamido-3-(1h-indol-3-yl)propanamido)-6-diazo-5-oxohexanoate for intravenous administration and the use thereof |
| WO2022022612A1 (en) * | 2020-07-29 | 2022-02-03 | Jacobio Pharmaceuticals Co., Ltd. | Novel glutamine analogs |
| WO2022072820A1 (en) * | 2020-10-02 | 2022-04-07 | Dracen Pharmaceuticals, Inc. | Lyophilized composition comprising (s)-isopropyl 2-((s)-2- acetamido-3-(1h-indol-3-yl)propanamido)-6-diazo-5- oxohexanoate for subcutaneous administration and the use thereof |
| AU2021361970A1 (en) | 2020-10-15 | 2023-06-15 | Jacobio Pharmaceuticals Co., Ltd. | Novel glutamine analogs |
| CN114621120B (zh) * | 2020-12-10 | 2023-11-03 | 深圳先进技术研究院 | 一种don前药分子、前药激活化合物和前药激活体系 |
| US20240246902A1 (en) * | 2021-04-29 | 2024-07-25 | The Johns Hopkins University | Prodrugs of 6-diazo-5-oxo-l-norleucine |
| WO2022261117A1 (en) * | 2021-06-07 | 2022-12-15 | Dracen Pharmaceuticals, Inc. | Combination therapy with a don prodrug and a tigit inhibitor |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5093330A (en) | 1987-06-15 | 1992-03-03 | Ciba-Geigy Corporation | Staurosporine derivatives substituted at methylamino nitrogen |
| US6605712B1 (en) | 1990-12-20 | 2003-08-12 | Arch Development Corporation | Gene transcription and ionizing radiation: methods and compositions |
| PL354286A1 (en) | 1999-08-23 | 2003-12-29 | Dana-Farber Cancer Institutedana-Farber Cancer Institute | Pd-1, a receptor for b7-4, and uses therefor |
| AU2003281200A1 (en) | 2002-07-03 | 2004-01-23 | Tasuku Honjo | Immunopotentiating compositions |
| DK2439273T3 (da) | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
| BR122017025062B8 (pt) | 2007-06-18 | 2021-07-27 | Merck Sharp & Dohme | anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento |
| AU2009288730B2 (en) | 2008-08-25 | 2013-06-20 | Amplimmune, Inc. | Compositions of PD-1 antagonists and methods of use |
| EP3255060A1 (en) | 2008-12-09 | 2017-12-13 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
| WO2013043569A1 (en) | 2011-09-20 | 2013-03-28 | Vical Incorporated | Synergistic anti-tumor efficacy using alloantigen combination immunotherapy |
| KR101764096B1 (ko) | 2011-11-28 | 2017-08-02 | 메르크 파텐트 게엠베하 | 항-ｐｄ-ｌ1 항체 및 그의 용도 |
| HK1203971A1 (en) | 2012-05-15 | 2015-11-06 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
| WO2015036499A1 (en) | 2013-09-11 | 2015-03-19 | Medimmune Limited | Anti-b7-h1 antibodies for treating tumors |
| AU2015225867B2 (en) | 2014-03-07 | 2020-02-06 | University Health Network | Methods and compositions for modifying the immune response |
| US20160113925A1 (en) * | 2014-10-22 | 2016-04-28 | Emory University | Methods of treating cancer with a combination of glucose modulators and bcl-2 inhibitors |
| EA034571B1 (ru) | 2015-07-31 | 2020-02-21 | Дзе Джонс Хопкинс Юниверсити | Пролекарства аналогов глутамина |
| CN108135872A (zh) | 2015-07-31 | 2018-06-08 | 约翰霍普金斯大学 | 用于治疗认知缺陷的谷氨酰胺拮抗剂 |
| CN108135875B (zh) | 2015-07-31 | 2021-12-31 | 约翰霍普金斯大学 | 用于治疗代谢重编程病症的方法和组合物 |
| WO2017040666A2 (en) * | 2015-08-31 | 2017-03-09 | Oncomed Pharmaceuticals, Inc. | Combination therapy for treatment of disease |
| EP3612839A1 (en) * | 2017-04-20 | 2020-02-26 | ADC Therapeutics SA | Combination therapy |
| EP3692015B1 (en) * | 2017-10-06 | 2022-08-24 | The John Hopkins University | Novel glutamine antagonists and uses thereof |
-
2020
- 2020-01-17 JP JP2021541578A patent/JP7574198B2/ja active Active
- 2020-01-17 EP EP20741361.8A patent/EP3911310A4/en not_active Withdrawn
- 2020-01-17 BR BR112021014112-0A patent/BR112021014112A2/pt not_active IP Right Cessation
- 2020-01-17 CA CA3126822A patent/CA3126822A1/en active Pending
- 2020-01-17 SG SG11202107317WA patent/SG11202107317WA/en unknown
- 2020-01-17 WO PCT/US2020/014149 patent/WO2020150639A1/en not_active Ceased
- 2020-01-17 US US17/423,819 patent/US20220117938A1/en not_active Abandoned
- 2020-01-17 EA EA202191992A patent/EA202191992A1/ru unknown
- 2020-01-17 AU AU2020208637A patent/AU2020208637A1/en not_active Abandoned
- 2020-01-17 CN CN202080013742.1A patent/CN113438947A/zh active Pending
- 2020-01-17 KR KR1020217026015A patent/KR20210117303A/ko not_active Ceased
- 2020-01-17 MX MX2021008546A patent/MX2021008546A/es unknown
-
2021
- 2021-07-18 IL IL284907A patent/IL284907A/en unknown